1. Prazosin in the treatment of prostatic obstruction;Kirby, R.S.; Coppinger, S.W.C.; Corcoran, M.V.; Chapple, C.R.; Flannigan, M.; Milroy, E.J.G.;Brj Urol,1987
2. United Kingdom Indoramin Study Group. Low dose indoramin, an alpha-adrenoreceptor antagonist, in the. management of benign prostatic hypertrophy;Gower, R.; Wells, P.;Neurourology and Urodynamics,1988
3. An inhibitor of S(t-reductase, MK-906 suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia;McConnell, J.D.; Wilson, J.D.; George, F.W.;J Urol,1989
4. Balloon dilatation of the prostate for the treatment of benign hyperplasia;Reddy, P.K.; Wasserman, N.; Castaneda, F.; Castaneda-Luniga, W.R.;Urol Clin North Am,1988
5. Use of stents for treating obstruction of urinary outflow in patients unfit for surgery;Williams, G.; Jager, R.; McLoughlin, L.;Br. Medj,1989